Last reviewed · How we verify
QLS1128 C-Dose 1~3 and Ritonavir — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
QLS1128 C-Dose 1~3 and Ritonavir (QLS1128 C-Dose 1~3 and Ritonavir) — Qilu Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| QLS1128 C-Dose 1~3 and Ritonavir TARGET | QLS1128 C-Dose 1~3 and Ritonavir | Qilu Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- QLS1128 C-Dose 1~3 and Ritonavir CI watch — RSS
- QLS1128 C-Dose 1~3 and Ritonavir CI watch — Atom
- QLS1128 C-Dose 1~3 and Ritonavir CI watch — JSON
- QLS1128 C-Dose 1~3 and Ritonavir alone — RSS
Cite this brief
Drug Landscape (2026). QLS1128 C-Dose 1~3 and Ritonavir — Competitive Intelligence Brief. https://druglandscape.com/ci/qls1128-c-dose-1-3-and-ritonavir. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab